Detalhe da pesquisa
1.
Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy.
J Hepatol
; 70(5): 1008-1015, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30982526
2.
Safety and efficacy of viramidine versus ribavirin in ViSER2: randomized, double-blind study in therapy-naive hepatitis C patients.
J Hepatol
; 52(1): 32-8, 2010 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19913323
3.
Improving outcomes for patients with chronic hepatitis B.
Curr Gastroenterol Rep
; 9(1): 14-22, 2007 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-17335673
4.
A pilot study of extended duration peginterferon alfa-2a for patients with hepatitis B e antigen-negative chronic hepatitis B.
Am J Gastroenterol
; 102(12): 2718-23, 2007 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-17662102
5.
Virological response and safety outcomes in therapy-nai ve patients treated for chronic hepatitis C with taribavirin or ribavirin in combination with pegylated interferon alfa-2a: a randomized, phase 2 study.
J Hepatol
; 47(1): 51-9, 2007 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-17470380
6.
Efficacy of interferon alpha-2b induction therapy before retreatment for chronic hepatitis C.
Liver Int
; 27(8): 1111-8, 2007 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-17845540
7.
Chronic hepatitis B: a critical appraisal of current approaches to therapy.
Clin Gastroenterol Hepatol
; 4(2): 233-48, 2006 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-16469685
8.
Eight genotypes (A-H) of hepatitis B virus infecting patients from San Francisco and their demographic, clinical, and virological characteristics.
J Med Virol
; 73(4): 516-21, 2004 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-15221894